Simone Klingenbrunner

Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables

Friedrich Erhart, Johanna Buchroithner, René Reitermaier et al. · Acta Neuropathologica Communications · 2018 · 59 citations · Full text

Medicine, Immunology, Oncology +17

EVI1 promotes tumor growth via transcriptional repression of MS4A3

Gerwin Heller, Anna Rommer, Katarina Steinleitner et al. · Journal of Hematology & Oncology · 2015 · 33 citations · Full text

Life Sciences, Molecular Biology, Oncology +15

Gliomasphere marker combinatorics: multidimensional flow cytometry detects <scp>CD</scp>44+/<scp>CD</scp>133+/<scp>ITGA</scp>6+/<scp>CD</scp>36+ signature

Friedrich Erhart, Bernadette Blauensteiner, Gabriel Zirkovits et al. · Journal of Cellular and Molecular Medicine · 2018 · 33 citations · Full text

Medicine, Cancer Biology, Oncology +17

Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors

Friedrich Erhart, Matthias Hackl, Hannes Hahne et al. · npj Vaccines · 2020 · 25 citations · Full text

Medicine, Immunology, Oncology +17

Spheroid glioblastoma culture conditions as antigen source for dendritic cell-based immunotherapy: spheroid proteins are survival-relevant targets but can impair immunogenic interferon γ production

Friedrich Erhart, Tamara Weiss, Simone Klingenbrunner et al. · Cytotherapy · 2019 · 10 citations

Medicine, Immunology, Oncology +17